Modulation of hepatitis B virus CCCDNA transcription
US9623071B2 · kind B2 · utility
27Cited by
0References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 31, 2013 |
| Grant date | Apr 18, 2017 |
| Priority date | — |
| Expiry date | May 31, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K5/126
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides small molecule inhibitors of hepatitis B virus (HBV) covalently closed circular (ccc) DNA, which are useful as therapeutics in the management of chronic HBV. The compounds of the invention achieve epigenetic modification of the cccDNA, histone modification and histone deacetylase activity inhibition, thus modulating HBV cccDNA. The present invention further provides methods for modulating HBV cccDNA, for treating or preventing HBV in a subject, and for modulating cccDNA transcription of hepatitis B in a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.